tetano
Editor, Senior Moderator
Br J Haematol
. 2020 Sep 10.
doi: 10.1111/bjh.17077. Online ahead of print.
Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia
Beatriz de la Cruz-Benito[SUP] 1 [/SUP], Mar?a I Rivas-Pollmar[SUP] 1 [/SUP], Mar?a T ?lvarez Rom?n[SUP] 1 [/SUP], Roberto Trelles-Mart?nez[SUP] 1 [/SUP], Monica Mart?n-Salces[SUP] 1 [/SUP], Paula L?zaro-Del Campo[SUP] 1 [/SUP], Andr?s Ram?rez-L?pez[SUP] 1 [/SUP], Sara Garc?a-Barcenilla[SUP] 1 [/SUP], Tamara Cebanu[SUP] 1 [/SUP], Paula Acu?a-Butta[SUP] 1 [/SUP], Elena Monz?n-Manzano[SUP] 1 [/SUP], Elena Gonz?lez-Zorrilla[SUP] 1 [/SUP], Victor Jim?nez-Yuste[SUP] 1 2 [/SUP], Nora V Butta[SUP] 1 [/SUP]
Affiliations
Abstract
Thrombocytopenia has been identified as a common complication of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the general population. In an attempt to determine the impact of coronavirus disease 2019 (COVID-19) in patients with immune thrombocytopenia (ITP), a retrospective single-centre study was performed. Thrombocytosis was observed in patients with chronic ITP after SARS-CoV-2 infection, frequently needing treatment adjustment or even discontinuation of therapy. Relapses and newly diagnosed cases showed a fast response after initial treatment compared to ITP. Reduced immune activity due to lymphopenia during COVID-19 could explain this paradoxical effect, although further studies are needed.
Keywords: COVID-19; SARS-CoV-2; immune thrombocytopenia; lymphopenia; thrombocytosis.
. 2020 Sep 10.
doi: 10.1111/bjh.17077. Online ahead of print.
Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia
Beatriz de la Cruz-Benito[SUP] 1 [/SUP], Mar?a I Rivas-Pollmar[SUP] 1 [/SUP], Mar?a T ?lvarez Rom?n[SUP] 1 [/SUP], Roberto Trelles-Mart?nez[SUP] 1 [/SUP], Monica Mart?n-Salces[SUP] 1 [/SUP], Paula L?zaro-Del Campo[SUP] 1 [/SUP], Andr?s Ram?rez-L?pez[SUP] 1 [/SUP], Sara Garc?a-Barcenilla[SUP] 1 [/SUP], Tamara Cebanu[SUP] 1 [/SUP], Paula Acu?a-Butta[SUP] 1 [/SUP], Elena Monz?n-Manzano[SUP] 1 [/SUP], Elena Gonz?lez-Zorrilla[SUP] 1 [/SUP], Victor Jim?nez-Yuste[SUP] 1 2 [/SUP], Nora V Butta[SUP] 1 [/SUP]
Affiliations
- PMID: 33280085
- DOI: 10.1111/bjh.17077
Abstract
Thrombocytopenia has been identified as a common complication of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the general population. In an attempt to determine the impact of coronavirus disease 2019 (COVID-19) in patients with immune thrombocytopenia (ITP), a retrospective single-centre study was performed. Thrombocytosis was observed in patients with chronic ITP after SARS-CoV-2 infection, frequently needing treatment adjustment or even discontinuation of therapy. Relapses and newly diagnosed cases showed a fast response after initial treatment compared to ITP. Reduced immune activity due to lymphopenia during COVID-19 could explain this paradoxical effect, although further studies are needed.
Keywords: COVID-19; SARS-CoV-2; immune thrombocytopenia; lymphopenia; thrombocytosis.